Third in line: Editas says it may partner up on commercialization of sickle cell gene therapy

Zachary Brennan

Senior Editor

Editas Medicine continues to churn along in a solid third place in the race against bluebird bio, and partners Vertex and CRISPR to commercialize the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Third in line: Editas says it may partner up on commercialization of sickle cell gene therapy

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Third in line: Ed­i­tas says it may part­ner up on com­mer­cial­iza­tion of sick­le cell gene ther­a­py

Senior Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Third in line: Editas says it may partner up on commercialization of sickle cell gene therapy